Acne vulgaris: Endocrine aspects;Acne vulgaris: Endocriene aspecten

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 23, 2006, Pages 1281-1285

  Dekkers, O M ^a   Thio, B H ^b   Romijn, J A ^a   Smit, J W A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTI ACNE AGENT; CYPROTERONE; ENZYME; ESTROGEN; HORMONE; SPIRONOLACTONE; TESTOSTERONE;

ACNE VULGARIS; ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; ENDOCRINE DISEASE; ENZYME ACTIVITY; HUMAN; OVARY POLYCYSTIC DISEASE; PREVALENCE; REVIEW; RISK FACTOR;

ACNE VULGARIS; ANDROGEN ANTAGONISTS; ANDROGENS; FEMALE; HUMANS; MALE; POLYCYSTIC OVARY SYNDROME; RECEPTORS, ANDROGEN;

EID: 33745748902     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41:577-80.
2. Dreno B, Poli F. Epidemiology of acne. Dermatology. 2003;206:7-10.
3. Blanken R, Voorst Vader PC van. Acne: pathogenese en therapie. Ned Tijdschr Geneeskd. 1983;127:1297-303.
4. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25:947-70.
5. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 2001;116:793-800.
6. Itami S, Takayasu S. Activity of 17 beta-hydroxysteroid dehydrogenase in various tissues of human skin. Br J Dermatol. 1981;105:693-9.
7. Labrie F, Luu-The V, Labrie C, Pelletier G, El-Alfy M. Intracrinology and the skin. Horm Res. 2000;54:218-29.
8. Thiboutot D, Martin P, Volikos L, Gilliland K. Oxidative activity of the type 2 isozyme of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) predominates in human sebaceous glands. J Invest Dermatol. 1998;111:390-5.
9. Choudhry R, Hodgins MB, Kwast TH van der, Brinkmann AO, Boersma WJ. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol. 1992;133:467-75.
10. Liang T, Hoyer S, Yu R, Soltani K, Lorincz AL, Hiipakka RA, et al. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 1993;100:663-6.
11. Pochi PE, Strauss JS. Sebaceous gland response in man to the administration of testosterone, delta-4-androstenedione, and dehydroisoandrosterone. J Invest Dermatol. 1969;52:32-6.
12. Lucky AW, Biro FM, Huster GA, Leach AD, Morrison JA, Ratterman J. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol. 1994;130:308-14.
13. Slayden SM, Moran C, Sams jr WM, Boots LR, Azziz R. Hyperandrogenemia in patients presenting with acne. Fertil Steril. 2001;75:889-92.
14. Thiboutot D, Gilliland K, Light J, Lookingbill D. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol. 1999;135:1041-5.
15. Borgia F, Cannavo S, Guarneri F, Cannavo SP, Vaccaro M, Guarneri B. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol. 2004;84:201-4.
16. Marynick SP, Chakmakjian ZH, McCafFree DL, Herndon jr JH. Androgen excess in cystic acne. N Engl J Med. 1983;308:981-6.
17. Walton S, Cunliffe WJ, Keczkes K, Early AS, McGarrigle HH, Katz M, et al. Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Br J Dermatol. 1995;133:249-53.
18. Cibula D, Hill M, Vohradnikova O, Kuzel D, Fanta M, Zivny J. The role of androgens in determining acne severity in adult women. Br J Dermatol. 2000;143:399-404.
19. Levell MJ, Cawood ML, Burke B, Cunliffe WJ. Acne is not associated with abnormal plasma androgens. Br J Dermatol. 1989;120:649-54.
20. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 1993;76:524-8.
21. Takayasu S, Wakimoto H, Itami S, Sano S. Activity of testosterone 5 alpha-reductase in various tissues of human skin. J Invest Dermatol. 1980;74:187-91.
22. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 15 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995;105:209-14.
23. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-62.
24. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.
25. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-9.
26. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006-11.
27. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-36.
28. Leyden J, Bergfeld W, Drake L, Dunlap F, Goldman MP, Gottlieb AB, et al. A systemic type 15 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol. 2004;50:443-7.
29. Ebling FJ, Randall VA. Steroid inhibitors of androgen-potentiated actions on skin. J Steroid Biochem. 1983;19:587-90.
30. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14:223-30.
31. Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne [Cochrane review]. Cochrane Database Syst Rev. 2004;(3):CD004425.
32. Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne. A randomized, placebo-controlled trial. J Am Acad Dermatol. 2002;47:399-409.
33. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37(5 Pt 1):746-54.
34. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89:615-22.
35. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgéstrel for acne treatment. Fertil Steril. 2001;76:461-8.
36. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003;206:57-67.
37. Poulin Y. Practical approach to the hormonal treatment of acne. J Cutan Med Surg. 2004;8 Suppl 4:16-21.
38. Tan J. Hormonal treatment of acne: review of current best evidence. J Cutan Med Surg. 2004;8 Suppl 4:11-5.
39. Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne [Cochrane review]. Cochrane Database Syst Rev. 2003;(4):CD000194.
40. James WD. Acne. N Engl J Med. 2005;352:1463-72.